Literature DB >> 20450350

Factors associated with mortality in transplant patients with invasive aspergillosis.

John W Baddley1, David R Andes, Kieren A Marr, Dimitrios P Kontoyiannis, Barbara D Alexander, Carol A Kauffman, Robert A Oster, Elias J Anaissie, Thomas J Walsh, Mindy G Schuster, John R Wingard, Thomas F Patterson, James I Ito, O Dale Williams, Tom Chiller, Peter G Pappas.   

Abstract

BACKGROUND: Invasive aspergillosis (IA) is an important cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. The purpose of this study was to evaluate factors associated with mortality in transplant patients with IA.
METHODS: Transplant patients from 23 US centers were enrolled from March 2001 to October 2005 as part of the Transplant Associated Infection Surveillance Network. IA cases were identified prospectively in this cohort through March 2006, and data were collected. Factors associated with 12-week all-cause mortality were determined by logistic regression analysis and Cox proportional hazards regression.
RESULTS: Six-hundred forty-two cases of proven or probable IA were evaluated, of which 317 (49.4%) died by the study endpoint. All-cause mortality was greater in HSCT patients (239 [57.5%] of 415) than in SOT patients (78 [34.4%] of 227; P<.001). Independent poor prognostic factors in HSCT patients were neutropenia, renal insufficiency, hepatic insufficiency, early-onset IA, proven IA, and methylprednisolone use. In contrast, white race was associated with decreased risk of death. Among SOT patients, hepatic insufficiency, malnutrition, and central nervous system disease were poor prognostic indicators, whereas prednisone use was associated with decreased risk of death. Among HSCT or SOT patients who received antifungal therapy, use of an amphotericin B preparation as part of initial therapy was associated with increased risk of death.
CONCLUSIONS: There are multiple variables associated with survival in transplant patients with IA. Understanding these prognostic factors may assist in the development of treatment algorithms and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20450350      PMCID: PMC2874071          DOI: 10.1086/652768

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program.

Authors:  J Morgan; K A Wannemuehler; K A Marr; S Hadley; D P Kontoyiannis; T J Walsh; S K Fridkin; P G Pappas; D W Warnock
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

2.  Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign.

Authors:  Reginald E Greene; Haran T Schlamm; Jörg-W Oestmann; Paul Stark; Christine Durand; Olivier Lortholary; John R Wingard; Raoul Herbrecht; Patricia Ribaud; Thomas F Patterson; Peter F Troke; David W Denning; John E Bennett; Ben E de Pauw; Robert H Rubin
Journal:  Clin Infect Dis       Date:  2006-12-29       Impact factor: 9.079

3.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation.

Authors:  A Wald; W Leisenring; J A van Burik; R A Bowden
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

4.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

Review 5.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation.

Authors:  P Ribaud; C Chastang; J P Latgé; L Baffroy-Lafitte; N Parquet; A Devergie; H Espérou; F Sélimi; V Rocha; H Espérou; F Sélimi; V Rocha; F Derouin; G Socié; E Gluckman
Journal:  Clin Infect Dis       Date:  1999-02       Impact factor: 9.079

7.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

8.  Combination antifungal therapy for invasive aspergillosis.

Authors:  Kieren A Marr; Michael Boeckh; Rachel A Carter; Hyung Woo Kim; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

9.  Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.

Authors:  Dimitrios P Kontoyiannis; Ray Hachem; Russell E Lewis; Gustavo A Rivero; Harrys A Torres; John Thornby; Richard Champlin; Hagop Kantarjian; Gerald P Bodey; Issam I Raad
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

10.  Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.

Authors:  Nina Singh; Ajit P Limaye; Graeme Forrest; Nasia Safdar; Patricia Muñoz; Kenneth Pursell; Sally Houston; Fernando Rosso; Jose G Montoya; Pamela Patton; Ramon Del Busto; Jose M Aguado; Robert A Fisher; Goran B Klintmalm; Rachel Miller; Marilyn M Wagener; Russell E Lewis; Dimitrios P Kontoyiannis; Shahid Husain
Journal:  Transplantation       Date:  2006-02-15       Impact factor: 4.939

View more
  100 in total

1.  Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study.

Authors:  Caroline Even; Sylvie Bastuji-Garin; Yosr Hicheri; Cécile Pautas; Francoise Botterel; Sébastien Maury; Ludovic Cabanne; Stéphane Bretagne; Catherine Cordonnier
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

Review 2.  [Specific infections in organ transplantation].

Authors:  M Cornberg; B Schlevogt; J Rademacher; A Schwarz; M Sandherr; G Maschmeyer
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

3.  In vitro combination of anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp.

Authors:  Virginie Planche; Sebastien Ducroz; Alexandre Alanio; Marie-Elisabeth Bougnoux; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

4.  A transcriptional signature accurately identifies Aspergillus Infection across healthy and immunosuppressed states.

Authors:  Julie M Steinbrink; Aimee K Zaas; Marisol Betancourt; Jennifer L Modliszewski; David L Corcoran; Micah T McClain
Journal:  Transl Res       Date:  2020-02-20       Impact factor: 7.012

5.  Infections in liver transplant recipients.

Authors:  Fabian A Romero; Raymund R Razonable
Journal:  World J Hepatol       Date:  2011-04-27

6.  Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience.

Authors:  D Neofytos; S Treadway; D Ostrander; C D Alonso; K L Dierberg; V Nussenblatt; C M Durand; C B Thompson; K A Marr
Journal:  Transpl Infect Dis       Date:  2013-02-21       Impact factor: 2.228

Review 7.  Treatment principles for the management of mold infections.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-06       Impact factor: 6.915

Review 8.  Antifungal clinical trials and guidelines: what we know and do not know.

Authors:  Peter G Pappas
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

9.  Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis.

Authors:  Simone Aranha Nouér; Marcio Nucci; Naveen Sanath Kumar; Monica Grazziutti; Alejandro Restrepo; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

10.  Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies.

Authors:  Sachiko Seo; Christian Renaud; Jane M Kuypers; Charles Y Chiu; Meei-Li Huang; Erik Samayoa; Hu Xie; Guixia Yu; Cynthia E Fisher; Ted A Gooley; Steven Miller; Robert C Hackman; David Myerson; Ruth H Sedlak; Yae-Jean Kim; Takahiro Fukuda; David N Fredricks; David K Madtes; Keith R Jerome; Michael Boeckh
Journal:  Blood       Date:  2015-04-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.